[1]李小侠,詹 颉,张 华,等.N-端脑钠肽前体测定在高血压疾病中的应用研究[J].现代检验医学杂志,2016,31(05):100-102.[doi:10.3969/j.issn.1671-7414.2016.05.027]
　LI Xiao-xia,ZHAN Jie,ZHANG Hua,et al.Application on NT-proBNP in Patients with Essential Hypertension[J].Journal of Modern Laboratory Medicine,2016,31(05):100-102.[doi:10.3969/j.issn.1671-7414.2016.05.027]
点击复制

N-端脑钠肽前体测定在高血压疾病中的应用研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第31卷
期数:
2016年05期
页码:
100-102
栏目:
论著
出版日期:
2016-10-21

文章信息/Info

Title:
Application on NT-proBNP in Patients with Essential Hypertension
文章编号:
1671-7414(2016)05-100-03
作者:
李小侠; 詹 颉; 张 华; 党小军; 赵 海; 奚逢瑜; 李 博
陕西省人民医院检验科,西安 710068
Author(s):
LI Xiao-xia; ZHAN Jie; ZHANG Hua; DANG Xiao-jun; ZHAOHai; XI Feng-yu; LI Bo
Department of Clinical Laboratory, Shaanxi Provincial People's Hospital,Xi'an 710068,China
关键词:
脑钠肽;  N-端脑钠肽前体;  高血压;  糖尿病
分类号:
R544.1; R446.112
DOI:
10.3969/j.issn.1671-7414.2016.05.027
文献标志码:
A
摘要:
目的 探讨血清N端脑钠肽前体(NT-proBNP)在高血压疾病的应用研究。方法 选择152例高血压患者纳入研究,根据高血压病情发展分为高血压1级(30例),高血压2级(36例)和高血压3级(86例)。86例高血压3级患者根据有无并发糖尿病又分为单纯高血压组(40例)和高血压并发糖尿病组(46例),分别比较不同分级组的血清NT-proBNP水平变化。结果 高血压1级患者、2级患者和3级患者血清中NT-proBNP水平分别为68±44,122±31和834±309 pg/ml。随着病情发展其血清水平逐渐升高(t=2.455,3.561,P<0.01),高血压3级患者中高血压并发糖尿病组和单纯高血压组血清中NT-proBNP分别为1 178±664 pg/ml和599±411 pg/ml(t=3.785,P<0.01)。结论 NT-proBNP水平能客观反映高血压患者的病情程度,对临床治疗和病情监测有一定的指导意义。
Abstract:
Objective To study the N terminal pro brain natriuretic peptide(NT-proBNP)in serum of hypertension patients.Methods 152 patients with hypertension were included in this study.According to the different degree and development of hypertension,152 patients weredivided into three different grade group of hypertension:first grade of hypertension group(30 patients),second grade of hypertension group(36 patients)andthird grade of hypertension group(86 patients).And the 86 patients were divided into hypertension group(40 patients)and hypertension with diabetes group(46 patients)respectively,comparaed with the level of NT-proBNP in serum of different hypertension grade groups.Results The levels of the NT-proBNP in serum were 68±44,122±31 and 834±309 pg/ml of first grade ofhypertension group,second grade of hypertension group and third grade of hypertension group,respectively.The level of the NT-proBNP was gradually increasedwith grade of hypertension(t=2.455,3.561,P<0.01).The level of the NT-proBNP(1 178±864 pg/ml)of hypertension with diabetes group was significantly higher than hypertension group(599±411 pg/ml)(t=3.785,P<0.01).Conclusion The level of NT-proBNP can objectively reflect thegrade of the disease in patients with hypertension.it is a certain significance guiding for monitoring the clinical treatment of the disease.

参考文献/References:

[1] Sudoh T,Kangawa K,Minamino N,et al.A new natriuretic peptidein porcine brain[J].Nature,1988,332(6159):78-81.
[2] Huang YT,Yuan-Teng T,Chu TW,et al.N-terminal pro B-type natriuretic peptide(NT-pro-BNP)-based score can predict in-hospital mortality in patientswith heart failure[J].Sci Rep,2016(6):29590.
[3] Azzazy HM,Christenson RH,Duh SH.Stability of B type natriuretic peptide(BNP)in whole blood and plasma stored under different conditions when measuredwith the Biosite Triage or Beckman-Coulter Access systems[J].Clin Chim Acta,2007,384(1/2):176-178.
[4] 周丽艳,笪应芬,谈介凡.慢性充血性心力衰竭患者血浆BNP含量与心脏结构和功能参数之间关系探讨[J].现代检验医学杂志,2011,26(3):51-52,55. Zhou LY,Da YF,Tan JF.Relationship between plasma BNP levels and echocardiographic measures of cardiac structure and function in patients with congestive heart failure[J].J Mod Lab Med,2011,26(3):51-52,55.
[5] Del Ry S,Maltinti M,Cabiati M.C-type natriuretic peptide and its relationto non-invasive indices of left ventricular function in patients with chronic heart failure[J].Peptides,2008,29(1):79-82.
[6] Passion C,Del Ry S,Severion S,et al.C-type natriuretic peptide expression in patients with chronic heart failure:effects of aerobic trainning[J].Eur J Cardiovasc Prev Rehabil,2008,15(2):168-172.
[7] Morillas P,Castillo J,Quiles J,et al.Usefulness of NT-proBNP level for diagnosing left ventricular hypertrophy in hypertensive patients acardiac magnetic resonance study[J].Rev Esp Cardiol,2008,61(9):972-975.
[8] Castano Rodrguez S,Coma Canella I,Lpez Salazar B,et al.Echocardiographic findings and NT-proBNP Level in type-2 diabetic patients with and withoutischemic heart disease[J].Rev Esp Cardiol,2009,62(10):1184-1188.
[9] Dencker M,Stagmo M,DorkhanM.Relationship between natriuretic peptide and echocardiography parameters in patients with poorly regulated type 2 diabetes[J].Vasc Health Risk Manag,2010(6):373-382.
[10] Tasi SH,Lin YY,Chu S J,et al.Interpretation and use of natriuretic peptides in non-congestive heart failure settings[J].Yonsei Med J,2010,51(2):151-163.
[11] Tagore R,Ling LH,Yang H,et al.Natriuretic peptide in chronic kidneydisease [J].Clin J Am SocNephrol,2008,3(6):1644-1651.

相似文献/References:

[1]郭飞波.CypA,BNP,ET-1浓度在老年慢性心衰患者中的表达及临床意义[J].现代检验医学杂志,2016,31(06):88.[doi:10.3969/j.issn.1671-7414.2016.06.025]
　GUO Fei-bo.Expression Characteristics and Clinical Significance of CypA,BNP and ET-1 in Elderly Patients with Chronic Heart Failure[J].Journal of Modern Laboratory Medicine,2016,31(05):88.[doi:10.3969/j.issn.1671-7414.2016.06.025]

备注/Memo

备注/Memo:

作者简介:李小侠(1976-),女,大学本科,主管检验师,主要从事临床检验工作。
通讯作者:张 华(1966-),女,大学本科,主管检验师,主要从事临床生化检验工作。
更新日期/Last Update: 2016-10-30